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currently unknown as definitions for MI have recently evolved
from a creatine kinase-based enzyme rise to a troponin-based rise.
Use of beta-blockers in patients with left ventricular (LV) impair-
ment is also strongly supported by numerous controlled trials, and
these patients should certainly receive beta-blockers post-CABG.
We agree that use of beta-blockers in patients without prior MI
(ST-segment or non–ST-segment elevation) or LV impairment is
more debatable.
We also believe there is sufficient evidence to warrant the use of
ACEI in most patients following CABG. In the Heart Outcomes
Prevention Evaluation (HOPE) trial, use of the ACEI ramipril
improved outcomes in patients with diabetes or known vascular
disease but without LV dysfunction (3); approximately 25% of the
participants had previously undergone CABG. The small study
evaluating quinapril post-CABG showed no effect of the ACEI on
the primary end point of change in exercise endurance or incidence
of ischemia on Holter monitor (4); however, fewer patients
receiving quinapril experienced ischemic events compared with
placebo (3.5% vs. 15%; p  0.02), suggesting benefit to those
receiving quinapril. Current research suggests that ACEI act as
vascular protective agents, and as such most patients undergoing
CABG for coronary disease are likely to benefit and should be
prescribed them.
We agree that aspirin and statins should be used post-CABG.
However, we also believe that ACEI should also be routinely used
where possible; use of beta-blockers should also be strongly
recommended especially in patients with a history of MI and/or
LV impairment.
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Cardiac Medical Therapy Following Coronary
Artery Bypass Graft Surgery
Okrainec et al. (1) meticulously reviewed available data from random-
ized studies of medical treatment for postcoronary artery bypass graft
(CABG) patients. Their recommendations should influence medical
practice until further information comes forth in the future.
Patients undergoing CABG at varying intervals after an acute
myocardial infarction (MI) are an important subgroup. They are
also an important subgroup undergoing percutaneous coronary
interventions. The efficacy of beta-blockers (2) and angiotensin-
converting enzyme (ACE) inhibitors (3) for secondary prevention
after an MI is established. No randomized controlled study has
addressed the issue of their usefulness in post-MI patients who
have undergone CABG. In the absence of evidence to the
contrary, it is prudent to assume that these agents will not lose
their efficacy after a post-MI patient undergoes CABG. Therefore,
it needs to be stated explicitly that, whereas there is little evidence
to suggest that beta-blockers and ACE inhibitors should be used
routinely after CABG, they should be used after CABG if the
patient had a prior MI. When future studies are planned, distin-
guishing this subgroup will be important.
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REPLY
We appreciate the interest in our study (1) expressed by Dr.
Chacko and Dr. Osman and colleagues. We agree that there is
substantial evidence supporting the use of beta-blockers and
angiotensin-converting enzyme (ACE) inhibitors among patients
with coronary artery disease (CAD) and other co-morbid condi-
tions. We also agree that a large proportion of post-coronary artery
bypass graft (CABG) patients should therefore receive these agents
including those with a history of myocardial infarction (MI), those
with a low ejection fraction, and those with congestive heart
failure. However, the routine use of these agents in all patients
post-CABG is not currently supported by large randomized
controlled trials (RCTs).
Few studies have examined the routine use of beta-blockers in
post-CABG patients. In a single RCT, no significant differences
were found in clinical end points including repeat revasculariza-
tion, unstable angina, nonfatal MI, or death at two-year follow-up
(2). Because many patients undergoing CABG are completely
revascularized, the benefits of prescribing beta-blockers in patients
without specific co-morbid conditions may be limited. Until large
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RCTs show a benefit with the routine use of beta-blockers in all
post-CABG patients, we think that treatment should be limited to
those patients with co-morbid conditions that are known to benefit
from beta-blocker therapy.
Similarly, only one RCT, the QUO VADIS study, examined
the routine use of ACE inhibitors in post-CABG patients (3).
Although this trial suggested a significant decrease in ischemic
events such as angina, death, MI, repeat revascularization, stroke,
or transient ischemic attacks in patients treated with quinapril,
only 149 patients were enrolled. Moreover, results from the
PEACE trial suggest there may be a limited role for ACE
inhibitors among patients with stable CAD and normal left
ventricular function (4). Thus, until large RCTs demonstrate a
benefit to the routine use of ACE inhibitors in all patients
post-CABG, we believe their use should be limited to patients
with co-morbid conditions known to benefit from ACE inhibitor
treatment.
Thus, we agree that the current literature supports the use of
beta-blockers and ACE inhibitors in various subgroups of CABG
patients with cardiac co-morbidities. However, we are hesitant to
recommend the routine use of these medications in all post-
CABG patients when sufficient data from placebo-controlled trials
do not exist. Larger RCTs, specifically conducted among CABG
patients, are needed before we can recommend the routine use of
beta-blockers and ACE inhibitors post-CABG.
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